For decades, the most powerful cholesterol-lowering treatments — PCSK9 inhibitors — have required injections every two to four weeks. Effective, yes. But the injection requirement meant lower patient compliance, clinic visits, and a significant barrier to treatment.
Now, a large Phase 3 trial published in the New England Journal of Medicine has shown that a once-daily pill called enlicitide can match that same power — taken at home, every morning, like a vitamin.
The Numbers Are Remarkable
The CORALreef Lipids trial enrolled 2,909 adults with or at high risk for heart disease. Results at 24 weeks:
- 55.8% reduction in LDL-C (bad cholesterol) versus placebo
- Post-hoc analysis: 59.7% reduction
- 67.5% of patients achieved at least 50% LDL reduction AND dropped below the target of 55 mg/dL
- Only 1.2% of the placebo group achieved the same
- Safety profile comparable to placebo — no serious additional risks observed
At one year, the reductions held: 47.6% below baseline (52.4% in post-hoc analysis).
Why This Matters
Cardiovascular disease kills more people globally than any other cause. Despite the availability of statins, tens of millions of people can't achieve safe LDL levels — either because statins aren't strong enough, or because side effects make them unworkable.
Injectable PCSK9 inhibitors like alirocumab and evolocumab exist, and they work. But compliance with injections is much lower than with pills. Converting an injection therapy into a daily pill isn't just convenient — it's potentially life-saving at scale.
"This could fundamentally change the landscape for patients who need more aggressive cholesterol management," said Dr. James Januzzi of Harvard Medical School, one of the trial investigators.
What's Next
Merck has submitted enlicitide for FDA review. An ongoing cardiovascular outcomes trial — CORALreef Outcomes — will determine whether the LDL reductions translate into fewer heart attacks and strokes, with results expected by late 2029.
But the evidence from Phase 3 is already compelling. Cardiologists are watching this closely.
Source: New England Journal of Medicine, March 2026 | Merck | CORALreef Lipids Trial | American Heart Association
